Dr. Benz has served as a member of the Board of Directors of Deciphera Pharmaceuticals since October 2016 and as the Chairperson of the Nominating and Corporate Governance Committee since September 2017. Dr. Benz is currently the Richard and Susan Smith Distinguished Professor of Medicine, Professor of Pediatrics, Professor of Pathology, and Faculty Dean Emeritus for Oncology at Harvard Medical School. From November 2000 until October 2016, Dr. Benz served as President and Chief Executive Officer of the Dana-Farber Cancer Institute, Chief Executive Officer of Dana-Farber/Partners CancerCare, Director of Dana-Farber/Harvard Cancer Center and a Trustee of Dana Farber/Children’s Hospital Cancer Care. Prior to joining Dana-Farber, Dr. Benz was Chairperson of the Department of Medicine and Physician in Chief at the Johns Hopkins University School of Medicine and the Sir William Osler Professor of Medicine. Dr. Benz is also a past president of the American Society of Hematology, the American Society of Clinical Investigation, the American Clinical and Climatological Association, the Friends of the National Institute of Nursing, and the Association of American Cancer Institutes. From March 2002 to June 2016, Dr. Benz served as an associate editor of the New England Journal of Medicine. He currently serves on the Boards of Directors of Candel Therapeutics, Renovacor, Inc., F-Star Biotechnology, Ltd., as well as non-profit organizations, including the Rockefeller University, MDI Biological Laboratory, and Mount Desert Island Hospital. Dr. Benz is the author of over 300 books, chapters, reviews and abstracts. Dr. Benz received an A.B. degree cum laude from Princeton University, an M.D. magna cum laude from Harvard Medical School, and an M.A. Privatim degree from Yale University.
